Semaglutide
Stock Recap #PipelineProspector

Pipeline Prospector August 2025: Novo’s Wegovy approved for MASH, Tonix Pharma’s fibromyalgia drug okayed

In August, the global pharmaceutical industry witnessed several regulatory upheavals and policy sh

Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals

The month of May saw investors grow increasingly cautious. This resulted in a dip in the biotech ind

Pipeline Prospector April 2025: Merck KGaA buys SpringWorks for US$ 3.9 bn; Swiss giants lead pharma migration to US soil

April witnessed considerable volatility in pharmaceutical stocks as the US President Donald Trump&rs

Pipeline Prospector March 2025: Trump’s FDA overhaul spooks biotech stocks; Roche, AbbVie, Novo ink obesity drug deals

March ended with news that the top vaccine regulator of the US Food and Drug Administration (FDA),

Pipeline Prospector Jan 2025: J&J’s US$ 14.6 bn Intra-Cellular buyout kicks off deal frenzy; Ozempic clinches FDA nod for CKD

January was a busy month that saw several deals being announced at the JP Morgan Healthcare Conferen

Pipeline Prospector 2024 highlights: Rise in new breed of biotechs with maiden approvals; GLP-1 meds show promise beyond obesity

December proved to be one of the most bearish months of 2024 for the biopharma sector. The Nasdaq Bi

Pipeline Prospector July 2024: Indices continue to climb; Lilly buys Morphic for US$ 3.2 bn, Kisunla bags FDA nod

The biotechnology sector ended in the green for the third month in a row in July, significantly outp

Pipeline Prospector June 2024: FDA approves Merck’s next-gen pneumococcal vaccine, Verona’s COPD therapy

The pharma indices were back in the black in May, and the good streak continued through June with th

Pipeline Prospector May 2024: J&J inks two deals for eczema drugs; Novo scores trial wins in hemophilia, kidney disease

Pharma indices have rebounded after ending March and April in the red. May saw the Nasdaq Biotechnol

Pipeline Prospector March 2024: FDA approves pathbreaking NASH drug from Madrigal, two meds for PAH

March was clearly a month of drug approvals, as the US Food and Drug Administration (FDA) went on a